• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Concert Pharmaceuticals

edit

Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.

Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.

Recent Milestones

edit

• 
  Concert Pharmaceuticals — Concert Pharma snags $200M licensing pact with Avanir (2/29/12)
  Posted 2/29/12 at 7:44pm via fiercebiotech.com
• 
  Concert Pharmaceuticals received $4M in Venture Round funding. (6/20/11)
  Posted 6/20/11 at 5:51pm via masshightech.com
• 
  Concert Pharmaceuticals — has made two new executive appointments (4/12/11)
  Posted 4/13/11 at 7:37am via masshightech.com
• 
  Concert Pharmaceuticals — Concert Pharmaceuticals, Walter Reed partner on seizure teatment (2/2/11)
  Posted 2/2/11 at 10:59pm via masshightech.com
• 
  Concert Pharmaceuticals — Concert Pharmaceuticals to land $12M from HIV drug's clinical study (11/9/09)
  Posted 11/9/09 at 12:01pm via masshightech.com
• 
  Concert Pharmaceuticals received $37M in Series C funding. (4/30/08)
  Posted 5/25/09 at 10:37pm
• 
  Concert Pharmaceuticals received $48.5M in Series B funding. (11/30/06)
  Posted 4/19/10 at 11:05pm via concertpharma.com
• 
  Concert Pharmaceuticals received $10M in Series A funding. (7/17/06)
  Posted 4/23/10 at 7:13pm via concertpharma.com
• 
  Concert Pharmaceuticals added Roger Tung as President and CEO.
  Posted 5/25/09 at 10:23pm
• 
  Concert Pharmaceuticals added Steve Bernitz as Chief Business Officer.
  Posted 5/25/09 at 10:23pm
• 
  Concert Pharmaceuticals added Nancy Stuart as COO.
  Posted 5/25/09 at 10:23pm
• 
  Concert Pharmaceuticals added Robert Silverman as Vice President and General Counsel.
  Posted 5/25/09 at 10:23pm
• 
  Concert Pharmaceuticals added Robert Zelle as Vice President, Drug Development.
  Posted 5/25/09 at 10:23pm

Videos

Screenshots

edit

Above: Homepage
Uploaded: 5/26/09

Sources

1. Concert Pharmaceuticals, Inc.,â„¢ Announces Financing of its Series A Round (concertpharma.com) [edit]
2. Concert Pharmaceuticals Raises $48.5 Million in Series B Financing (concertpharma.com) [edit]
3. Capital Funding Report [edit]
4. Concert Pharmaceuticals lands $4M milestone pay (masshightech.com) [edit]
Mass High Tech (masshightech.com) [edit]
Concert Pharmaceuticals, Walter Reed partner on seizure teatment (masshightech.com) [edit]
Concert Pharmaceuticals names Roessel, Sabounjian to exec roles (masshightech.com) [edit]
Concert Pharma snags $200M licensing pact with Avanir (fiercebiotech.com) [edit]